Curative treatment is feasible for recurrent hepatocellular carcinoma regardless of recurrence pattern after hepatitis C virus eradication with interferon-free direct-acting antiviral therapy Authors: Satoru Hagiwara, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Yoriaki Komeda, Kazuomi Ueshima, Yasunori Minami, Masahiro Takita, Masahiro Morita, Hirokazu Chishina, Akihiro Yoshida, Naoshi Nishida, Masatoshi Kudo Published: 2026 ABSTRACT BackgroundInterferon (IFN)-free direct-acting antivirals (DAAs) have significantly improved hepatitis C virus (HCV) elimination rates. However, new-onset or recurrence of hepatocellular carcinoma (HCC) remains common even after achieving sustained virological response (SVR). This study investigated the clinical significance and treatability of HCC recurrence patterns after SVR, which have not been fully explored yet.MethodsWe retrospectively analyzed the risk factors for HCC development in 279 patients with HCV-associated chronic liver disease who achieved SVR with DAA therapy after July 2014. Twenty-eight patients with HCC recurrence after SVR were classified by the type of recurrence (intrahepatic metastasis, hypervascularization, and de novo). Correlation between tumor markers (alpha-fetoprotein and des-γ-carboxy prothrombin) at the time of previous HCC and at the time of recurrence was examined.ResultsThirty-three patients (11.8%) developed HCC after SVR. Multivariate analysis revealed that a history of HCC was the only independent risk factor for HCC development after SVR (hazard ratio 14.4, P < 0.001). Among the 28 patients with HCC recurrence, intrahepatic metastasis was observed in eight (29%), hypervascularization in seven (25%), and de novo recurrence in six (21%) patients. At the time of recurrence, 27 patients (96%) had Barcelona clinic liver cancer stage 0/A disease. Curative treatment was possible in 27 patients (96%).ConclusionsHCC recurrence after SVR was detected early, regardless of the recurrence pattern, allowing for the selection of curative treatment. In the DAA era, HCC recurrence after SVR in patients with a history of HCC could be appropriately managed through strict follow-up. Background Hepatitis C virus (HCV) infection is one of the major causes of liver cirrhosis and hepatocellular carcinoma (HCC) [1, 2]. In recent years, the introduction of direct-acting antivirals (DAAs) that do not use interferon (IFN) has dramatically improved HCV elimination rates, enabling many patients to achieve sustained virological response (SVR) [3]. Achieving SVR quells hepatitis activity and improves the hepatic functional reserve, thus reducing the risk of HCC development [4]. However, new incidence as well as recurrence of HCC are still observed among patients who achieved SVR after DAA treatment. Therefore, continued strict surveillance is necessary, especially in patients with a history of HCC, even after SVR [5]. The clinical characteristics and recurrence patterns of HCC that develops or recurs after DAA treatment remain unclear. There is considerable debate regarding whether post-SVR HCC recurrence corresponds to intrahepatic metastasis, hypervascularization, or de novo carcinogenesis; tumor biology of the different recurrence modes; and their implications for treatability and prognosis. Until now, the recurrence patterns of HCC have been classified mainly based on the timing and location of recurrence, but no studies have confirmed the validity of these definitions in the clinical context after DAA therapy. Furthermore, no studies have comprehensively evaluated the tumor stage, treatment options, and cure potential at the time of HCC recurrence. In order to formulate HCC management strategies in the DAA era, it is crucial to clarify whether early detection and curative treatment of HCC recurrence after SVR are possible. This study aimed to (i) investigate the risk factors for HCC development in patients with HCV-induced chronic liver disease who achieved SVR after DAA therapy; (ii) identify the HCC recurrence modes after SVR; (iii) verify the validity of these definitions by evaluating the correlation of tumor markers (TM) with different recurrence modes; and (iv) clarify the tumor stage at recurrence, treatment options, and therapeutic effects. Overall, we aimed to demonstrate that curative treatment can be selected at a high rate for relapsed HCC after IFN-free DAA treatment, regardless of the relapse pattern, and to clarify the clinical significance of HCC recurrence after SVR. Methods Study design In this retrospective study, among the 316 patients who were treated with DAAs for chronic HCV-hepatitis since July 2014, we examined cancer risk factors in 279 patients after excluding 37 patients who developed HCC during DAA treatment or failed to achieve SVR (Fig. 1). Thirty-three of the 279 patients (11.8%) developed new HCC or recurrent HCC after SVR. Of these, 28 patients had recurrent HCC, and the HCC recurrence pattern was examined in these patients. Furthermore, in patients with recurrent HCC, the TM at the time of the most recent HCC onset were compared with those at the time of recurrent HCC after SVR to confirm the reliability of the definition of the HCC recurrence pattern. Finally, the cancer stage, treatment, and therapeutic effect at the time of HCC recurrence were evaluated. Clinical trial number: not applicable. Fig. 1Study design. Of the 316 patients treated with direct-acting antivirals (DAAs) for chronic hepatitis C since July 2014, the risk factors for liver cancer were examined in 279 patients, excluding 37 patients who developed liver cancer during DAA treatment or who failed to achieve a sustained viral response (SVR) Study design. Of the 316 patients treated with direct-acting antivirals (DAAs) for chronic hepatitis C since July 2014, the risk factors for liver cancer were examined in 279 patients, excluding 37 patients who developed liver cancer during DAA treatment or who failed to achieve a sustained viral response (SVR) Liver cancer recurrence patterns (Fig. 2) Fig. 2Liver cancer recurrence patterns. (1) Hypervascularization: Computed tomography (CT) scans obtained before hepatocellular carcinoma (HCC) onset show no tumor enhancement in the arterial phase or portal vein washout. At the time of HCC onset, tumor enhancement in the arterial phase corresponds to the portal vein washout area. (2) Intrahepatic metastasis: Recurrence in the same lobe that underwent previous HCC treatment, occurring within 2 years of previous HCC radical resection. (3) De novo: Recurrence in a different lobe from the one that underwent previous HCC treatment, or recurrence in the same lobe that underwent previous HCC treatment but more than 2 years after the previous HCC radical surgery Liver cancer recurrence patterns. (1) Hypervascularization: Computed tomography (CT) scans obtained before hepatocellular carcinoma (HCC) onset show no tumor enhancement in the arterial phase or portal vein washout. At the time of HCC onset, tumor enhancement in the arterial phase corresponds to the portal vein washout area. (2) Intrahepatic metastasis: Recurrence in the same lobe that underwent previous HCC treatment, occurring within 2 years of previous HCC radical resection. (3) De novo: Recurrence in a different lobe from the one that underwent previous HCC treatment, or recurrence in the same lobe that underwent previous HCC treatment but more than 2 years after the previous HCC radical surgery Hypervascularization Computer tomography (CT) scan before HCC onset shows no tumor enhancement in the arterial phase and portal vein washout. At the time of HCC onset, tumor enhancement in the arterial phase is observed in the area corresponding to the portal vein washout. Intrahepatic metastasis Recurrence in the same lobe that was treated previously for HCC within 2 years of the previous HCC curative surgery. De novo Recurrence in a different lobe from the one that underwent previous HCC treatment, or recurrence in the same lobe that was treated previously for HCC but occurring more than 2 years after the previous HCC curative surgery. Statistical analysis Univariate and multivariate Cox regression analyses were performed to examine the risk factors for HCC. Kaplan–Meier curves were created and analyzed using the log-rank test to determine the cumulative cancer incidence rates. In addition, to examine the recurrence patterns of HCC, TM at the time of the previous HCC were compared with those at the time of HCC recurrence after SVR, and Pearson’s correlation coefficient (R value) and Spearman’s rank correlation coefficient (P value) were calculated. Statistical significance was set at P < 0.05. All statistical analyses were performed using SPSS software (version 29; SPSS Inc., Chicago, IL, USA). Results Patient characteristics (Table 1) A total of 279 patients were analyzed (Table 1), with a median age of 68 years and median fibrosis-4 (FIB4-index) of 5.0. Sixty-five patients (23%) had a history of HCC. A total of 68 patients (24%) had diabetes mellitus (DM), 35 (13%) had hepatic leukemia (HL), 140 (50%) had hypertension, and 85 (30%) had fatty liver. Thirty-three patients (11.8%) developed HCC after SVR. The median follow-up duration was 23 months. Table 1Baseline clinical characteristics of the patientsClinical factorsAll patientsSex (Male / Female)127/152Age (years) (Median, Range)68 (26–90)HCV-RNA (log IU/L) (Median, Range)5.9 (2.2–7.6)FIB-4 index (Median, Range)5.0 (0.4–31)APRI (Median, Range)1.7 (0.1–14.6)AST level (U/L) (Median, Range)52.1 (11–292)ALT level (U/L) (Median, Range)50 (6–506)Albumin level (g/dL) (Median, Range)3.9 (2.3–5.1)Platelet counts (×104/mL) (Median, Range)14.2 (2.5–40.6)AFP level (ng/mL) (Median, Range)16.1 (1–701)Previous antiviral treatment (with/without)73/206Past history of HCC (with/without)65/214Diabetes mellitus (with/without)68/211Hyperlipidemia (with/without)35/244Hypertension (with/without)140/139Fatty liver (with/without)85/194Hepatocarcinogenesis after SVR (with/without)33/246Follow-up period (month) (Median, Range)23 (1–34)HCV Hepatitis C Virus, FIB4-index Fibrosis-4 index, APRI AST to Platelet Ratio Index, AST Aspartate aminotransferase, ALT Alanine aminotransferase, AFP Alpha-fetoprotein, SVR sustained virological response Table 1Baseline clinical characteristics of the patientsClinical factorsAll patientsSex (Male / Female)127/152Age (years) (Median, Range)68 (26–90)HCV-RNA (log IU/L) (Median, Range)5.9 (2.2–7.6)FIB-4 index (Median, Range)5.0 (0.4–31)APRI (Median, Range)1.7 (0.1–14.6)AST level (U/L) (Median, Range)52.1 (11–292)ALT level (U/L) (Median, Range)50 (6–506)Albumin level (g/dL) (Median, Range)3.9 (2.3–5.1)Platelet counts (×104/mL) (Median, Range)14.2 (2.5–40.6)AFP level (ng/mL) (Median, Range)16.1 (1–701)Previous antiviral treatment (with/without)73/206Past history of HCC (with/without)65/214Diabetes mellitus (with/without)68/211Hyperlipidemia (with/without)35/244Hypertension (with/without)140/139Fatty liver (with/without)85/194Hepatocarcinogenesis after SVR (with/without)33/246Follow-up period (month) (Median, Range)23 (1–34)HCV Hepatitis C Virus, FIB4-index Fibrosis-4 index, APRI AST to Platelet Ratio Index, AST Aspartate aminotransferase, ALT Alanine aminotransferase, AFP Alpha-fetoprotein, SVR sustained virological response Baseline clinical characteristics of the patients HCV Hepatitis C Virus, FIB4-index Fibrosis-4 index, APRI AST to Platelet Ratio Index, AST Aspartate aminotransferase, ALT Alanine aminotransferase, AFP Alpha-fetoprotein, SVR sustained virological response Risk factors for cancer development The analyzed variables (Table 2) included age; sex; FIB4-index; presence or absence of DM; presence or absence of HT; presence or absence of HL; albumin (ALB), platelet (PLT), alanine aminotransferase (ALT), and alpha-fetoprotein (AFP) levels before DAA treatment; ALB, PLT, ALT, and AFP levels 12 weeks after DAA treatment; and history of HCC. Univariate analysis identified sex, ALB levels before DAA treatment, PLT levels before and after DAA treatment, AFP levels before and after DAA treatment, and history of HCC as significant factors for HCC development. In multivariate analysis, history of HCC remained the only significant factor (hazard ratio, 14.421; 95% confidence interval [CI] 4.768–43.618, P < 0.001). On comparing the cumulative cancer incidence rates, patients with a history of HCC had a significantly higher incidence of HCC after SVR than those without a history of HCC (P < 0.001) (Fig. 3). Table 2Cox regression analysis for risk factors for HCC (including history of HCC)FactorsCategoryUnivariate analysisHazard ratio (95% CI) P valueMultivariate analysisHazard ratio (95% CI) P valueAge, years0: <631: ≥6312.471 (0.865–7.063)0.091Sex0: female1: male15.170 (1.813–14.742)0.002FIB-4 index0: <3.251: ≥3.2511.385 (0.605–3.168)0.441Diabetes mellitus0: Absent1: Present10.600 (0.259–1.392)0.234Hypertension0: Absent1: Present11.432 (0.707–2.901)0.319Hyperlipidemia0: Absent1: Present10.449 (0.107–1.878)0.273Pre Albumin, g/dL0: <3.21: ≥3.210.201 (0.083–0.419)< 0.001Post Albumin, g/dL0: <4.31: ≥4.310.803 (0.397–1.627)0.543Pre Platelet count, ×104/mL0: <8.51: ≥8.510.191 (0.166–0.696)< 0.001Post Platelet count, ×104/mL0: <13.11: ≥13.110.340 (0.231–1.019)0.003Pre ALT, IU/L0: <281: ≥2812.201 (0.952–5.088)0.065Post ALT, IU/L0: <111: ≥1112.367 (0.721–7.771)0.156Pre AFP, ng/mL0: <61: ≥614.968 (2.148–11.493)< 0.001Post AFP, ng/mL0: <31: ≥3146.836 (2.050–1069.800)0.016HCC history0: Absent1: Present127.190 (9.503–77.793)< 0.001114.421 (4.768–43.618)< 0.001ALT Alanine aminotransferase, AFP Alpha-fetoprotein, HCC Hepatocellular carcinoma, HR hazard ratio, CI confidence interval, FIB4-index Fibrosis-4 index Table 2Cox regression analysis for risk factors for HCC (including history of HCC)FactorsCategoryUnivariate analysisHazard ratio (95% CI) P valueMultivariate analysisHazard ratio (95% CI) P valueAge, years0: <631: ≥6312.471 (0.865–7.063)0.091Sex0: female1: male15.170 (1.813–14.742)0.002FIB-4 index0: <3.251: ≥3.2511.385 (0.605–3.168)0.441Diabetes mellitus0: Absent1: Present10.600 (0.259–1.392)0.234Hypertension0: Absent1: Present11.432 (0.707–2.901)0.319Hyperlipidemia0: Absent1: Present10.449 (0.107–1.878)0.273Pre Albumin, g/dL0: <3.21: ≥3.210.201 (0.083–0.419)< 0.001Post Albumin, g/dL0: <4.31: ≥4.310.803 (0.397–1.627)0.543Pre Platelet count, ×104/mL0: <8.51: ≥8.510.191 (0.166–0.696)< 0.001Post Platelet count, ×104/mL0: <13.11: ≥13.110.340 (0.231–1.019)0.003Pre ALT, IU/L0: <281: ≥2812.201 (0.952–5.088)0.065Post ALT, IU/L0: <111: ≥1112.367 (0.721–7.771)0.156Pre AFP, ng/mL0: <61: ≥614.968 (2.148–11.493)< 0.001Post AFP, ng/mL0: <31: ≥3146.836 (2.050–1069.800)0.016HCC history0: Absent1: Present127.190 (9.503–77.793)< 0.001114.421 (4.768–43.618)< 0.001ALT Alanine aminotransferase, AFP Alpha-fetoprotein, HCC Hepatocellular carcinoma, HR hazard ratio, CI confidence interval, FIB4-index Fibrosis-4 index Cox regression analysis for risk factors for HCC (including history of HCC) 0: <63 1: ≥63 1 2.471 (0.865–7.063) 0: female 1: male 1 5.170 (1.813–14.742) 0: <3.25 1: ≥3.25 1 1.385 (0.605–3.168) 0: Absent 1: Present 1 0.600 (0.259–1.392) 0: Absent 1: Present 1 1.432 (0.707–2.901) 0: Absent 1: Present 1 0.449 (0.107–1.878) 0: <3.2 1: ≥3.2 1 0.201 (0.083–0.419) 0: <4.3 1: ≥4.3 1 0.803 (0.397–1.627) 0: <8.5 1: ≥8.5 1 0.191 (0.166–0.696) 0: <13.1 1: ≥13.1 1 0.340 (0.231–1.019) 0: <28 1: ≥28 1 2.201 (0.952–5.088) 0: <11 1: ≥11 1 2.367 (0.721–7.771) 0: <6 1: ≥6 1 4.968 (2.148–11.493) 0: <3 1: ≥3 1 46.836 (2.050–1069.800) 0: Absent 1: Present 1 27.190 (9.503–77.793) 1 14.421 (4.768–43.618) ALT Alanine aminotransferase, AFP Alpha-fetoprotein, HCC Hepatocellular carcinoma, HR hazard ratio, CI confidence interval, FIB4-index Fibrosis-4 index Fig. 3Cancer risk factors. On comparing the cumulative cancer incidence rates, patients with a history of hepatocellular carcinoma (HCC) had a significantly higher incidence of HCC after sustained viral response (SVR) than those without a history of HCC (P < 0.001) Cancer risk factors. On comparing the cumulative cancer incidence rates, patients with a history of hepatocellular carcinoma (HCC) had a significantly higher incidence of HCC after sustained viral response (SVR) than those without a history of HCC (P < 0.001) HCC recurrence patterns Of the 33 patients who developed HCC after SVR, 28 had HCC recurrence. Among these 28 patients, intrahepatic metastasis occurred in eight (29%), hypervascularization in seven (25%), and de novo HCC in six (21%) patients (Fig. 4). One patient experienced recurrence due to portal vein tumor thrombosis after SVR. To examine the HCC recurrence patterns, we compared TM at the time of the preceding HCC with those at the time of HCC recurrence after SVR. In patients with intrahepatic metastasis, des-γ-carboxy prothrombin (DCP) levels at the time of the preceding HCC showed a significant correlation with those after SVR (Fig. 5). AFP levels also showed a tendency toward a significant correlation. However, in patients with hypervascularization, no significant correlation was observed between AFP and DCP levels at the time of the preceding HCC and those at the time of HCC recurrence after SVR. In patients with de novo HCC, no significant correlation was observed for DCP. These findings confirm the validity of the definitions of HCC recurrence patterns. Fig. 4Hepatocellular carcinoma (HCC) recurrence patterns. Of the 33 patients who developed HCC after achieving sustained viral response (SVR), 28 had HCC recurrence. Analysis of the HCC recurrence patterns in these 28 patients revealed intrahepatic metastasis in eight (29%), hypervascularization in seven (25%), and de novo HCC in six (21%) cases. One patient experienced recurrence due to portal vein tumor thrombosis after SVR TACE, transarterial chemoembolization Hepatocellular carcinoma (HCC) recurrence patterns. Of the 33 patients who developed HCC after achieving sustained viral response (SVR), 28 had HCC recurrence. Analysis of the HCC recurrence patterns in these 28 patients revealed intrahepatic metastasis in eight (29%), hypervascularization in seven (25%), and de novo HCC in six (21%) cases. One patient experienced recurrence due to portal vein tumor thrombosis after SVR TACE, transarterial chemoembolization Fig. 5Liver cancer recurrence patterns. Tumor markers at the time of previous hepatocellular carcinoma (HCC) onset were compared with those at the time of HCC recurrence after sustained viral response (SVR). In patients with intrahepatic metastasis, a significant correlation was found between the des-γ-carboxy prothrombin (DCP) value at the time of previous HCC onset and that after SVR. There was also a tendency for a significant correlation between the alpha-fetoprotein (AFP) values. However, in cases with hypervascularization, no significant correlation was observed between AFP and DCP values at the time of previous HCC onset and those after SVR; in de novo cases, no significant correlation was observed for DCP Liver cancer recurrence patterns. Tumor markers at the time of previous hepatocellular carcinoma (HCC) onset were compared with those at the time of HCC recurrence after sustained viral response (SVR). In patients with intrahepatic metastasis, a significant correlation was found between the des-γ-carboxy prothrombin (DCP) value at the time of previous HCC onset and that after SVR. There was also a tendency for a significant correlation between the alpha-fetoprotein (AFP) values. However, in cases with hypervascularization, no significant correlation was observed between AFP and DCP values at the time of previous HCC onset and those after SVR; in de novo cases, no significant correlation was observed for DCP Stage, treatment, and therapeutic effect at the time of HCC recurrence after SVR (Table 3) Table 3Stage, treatment, and therapeutic effect in HCC after SVRRecurrence of HCC(n = 28)BCLC stage (0/A/B/C)12/15/0/1Treatment of HCCresection/RFA/TACE/HAIC1/25/2†/1Successful complete remission, n, (%)27 (96%)HCC hepatocellular carcinoma, SVR sustained virologic response, BCLC Barcelona clinic liver cancer, RFA Radiofrequency ablation, TACE Transarterial chemoembolization, HAIC Hepatic arterial infusion chemotherapy†RFA with TACE Table 3Stage, treatment, and therapeutic effect in HCC after SVRRecurrence of HCC(n = 28)BCLC stage (0/A/B/C)12/15/0/1Treatment of HCCresection/RFA/TACE/HAIC1/25/2†/1Successful complete remission, n, (%)27 (96%)HCC hepatocellular carcinoma, SVR sustained virologic response, BCLC Barcelona clinic liver cancer, RFA Radiofrequency ablation, TACE Transarterial chemoembolization, HAIC Hepatic arterial infusion chemotherapy†RFA with TACE Stage, treatment, and therapeutic effect in HCC after SVR Treatment of HCC resection/RFA/TACE/HAIC HCC hepatocellular carcinoma, SVR sustained virologic response, BCLC Barcelona clinic liver cancer, RFA Radiofrequency ablation, TACE Transarterial chemoembolization, HAIC Hepatic arterial infusion chemotherapy †RFA with TACE Among 28 patients with recurrent HCC, the disease stage at the time of recurrence was BCLC stage 0 in 12 patients, stage A in 15 patients, stage B in none of the patients, and stage C in one patient. Treatment options used at the time of recurrence included resection in one patient, radiofrequency ablation (RFA) in 25, transarterial chemoembolization + RFA in two, and hepatic arterial infusion chemotherapy (HAIC) in one patient. Curative treatment was possible for 27 cases (96%) of HCC. The only cases where curative treatment could not be performed were those that recurred with portal vein tumor thrombus after sustained villus respiration (SVR). Although HAIC was performed in these cases, they progressed to liver failure and died prematurely. Discussion In this study, we found that a history of HCC was the most important risk factor for HCC development after SVR. Furthermore, HCC recurrence after SVR was often detected at an early stage, regardless of the recurrence pattern, and was highly curable. This study is significant as it clarifies the clinical features of HCC recurrence in the DAA era and clearly demonstrates its treatability. A history of HCC was found to be the only independent significant risk factor for HCC development after SVR, whereas age, FIB4-index, metabolic factors such as DM and dyslipidemia, and factors related to liver function before and after DAA treatment lost significance in the multivariate analysis. This may reflect the fact that while DAA treatment improves the inflammatory activity and hepatic reserve, in cases where HCC has already occurred, the ability of the liver to act as a carcinogenic site remains strong. Previous studies have shown that the risk of cancer recurrence persists in patients with a history of HCC, even after achieving SVR [5–7], and the results of this study support these findings. Recently, IFN-free DAAs have been increasingly used as antiviral therapy after curative treatment for liver cancer because of their low side effects, high SVR rates, relatively short treatment duration, and applicability in compensated liver cirrhosis. However, the effectiveness of DAAs in preventing liver cancer recurrence remains controversial. Reig et al. from Spain reported that in patients who received DAAs without radiological evidence of nodular lesions after HCC treatment, a high rate of liver cancer recurrence was observed during short-term follow-up, suggesting that DAAs may promote liver cancer recurrence [8]. It has been speculated that the rapid clearance of HCV by DAAs without immunomodulatory effects may be responsible for a shift in the host immune balance. Subsequently, Conti et al. from Italy and Yang et al. from the United States reported relatively high rates of HCC recurrence after DAA treatment, temporarily raising concerns about the association between DAA treatment and HCC recurrence [9, 10]. However, these studies have been criticized for their short observation periods, limited case numbers, and inadequate adjustment for background factors, such as tumor characteristics and prior treatment. Camma et al. reanalyzed the same data as Reig et al. and found that when observation was initiated at the time of complete cure, the recurrence rate was not higher than that in the general population [11]. Recent evidence has shown that DAAs have a similar recurrence suppression effect as IFN-based therapy, or even lead to a significant reduction in recurrence compared with antiviral therapy-naïve patients [12]. In a retrospective pooled analysis by Petta et al., the recurrence rate after IFN-free DAA treatment was comparable to that after IFN-based therapy and significantly lower than that in antiviral therapy-naïve patients [13]. Furthermore, systematic reviews and meta-analyses have shown no difference in the rates of de novo liver cancer and liver cancer recurrence between IFN-free and IFN-based therapy, and patients who achieved SVR demonstrated better overall and recurrence-free survival [14]. In a Japanese study, Nagata et al. used propensity score matching to compare IFN-free DAA therapy with IFN-based therapy in patients who had undergone curative treatment for newly diagnosed HCC based on the Milan criteria, and found no difference in the recurrence rate between the two groups [15]. Ikeda et al. reported that patients who underwent DAA therapy after curative treatment for HCC had a significantly lower recurrence rate than those who did not receive antiviral therapy [16]. These results suggest that DAA therapy does not increase the risk of HCC recurrence and achieving SVR may be effective in suppressing liver carcinogenesis and improving survival. In this study, although HCC recurrence after SVR was observed in certain cases, most cases were diagnosed at an early stage (BCLC stage 0 or A), and curative treatment was possible in 96% of cases, regardless of the type of recurrence. These results indicate that HCC recurrence after DAA therapy does not necessarily have a poor prognosis and the risk can be adequately managed with strict surveillance. Furthermore, analysis by recurrence type revealed a correlation between DAA therapy and TM only in cases with intrahepatic metastasis, suggesting that the definition of recurrence type may have some validity from a biological tumor perspective. However, no differences in treatment outcomes were observed based on the recurrence type. Previous studies have suggested that intrahepatic metastasis may have a worse prognosis than de novo recurrence [17], but the results of this study emphasize the importance of early detection rather than the recurrence type itself. The identification of cases of advanced HCC with portal vein tumor thrombosis even after SVR is an important finding. Occasional cases of unexpectedly advanced HCC recurrence after DAA treatment have been reported [8–10], emphasizing the need for strict surveillance even after antiviral therapy. Future studies should more strictly distinguish between intrahepatic metastasis and de novo recurrence, and consider the differentiation and molecular malignancy level at the time of recurrence, in addition to the recurrence type [18, 19]. The limitations of this study are clearly stated. Regarding the study design, a total of 37 patients who developed HCC during DAA treatment and those who did not achieve SVR were excluded from the analysis. Therefore, selection bias may have occurred, such as the exclusion of highly malignant tumors. In addition, although 96% of HCC recurrence patients were able to choose curative treatment, this does not mean a cure. Therefore, the possibility of late recurrence cannot be ruled out. In the examination of HCC recurrence risk factors, the focus was mainly on patient characteristics, but tumor size and the presence or absence of vascular invasion were not evaluated, which may have resulted in confounding bias. Furthermore, stratified analysis by past hepatocellular carcinoma treatment history and recurrence interval was not performed, so the confounding effect of past treatment intensity on recurrence prognosis could not be eliminated. Other limitations include the fact that it is a retrospective single-center study with a limited number of cases, that the evaluation of recurrence patterns is based on imaging and clinical course without molecular biological analysis, and that the observation period is relatively short. In the future, it is necessary to further clarify the actual situation of HCC recurrence after DAA treatment through multicenter collaborative studies and studies that include long-term prognosis. Conclusion In patients with chronic hepatitis C who achieved SVR after IFN-free DAA treatment, history of HCC was the most important risk factor for HCC development after SVR. However, HCC recurrence after SVR if detected early is highly curable, regardless of the recurrence pattern. Based on the current evidence, IFN-free DAA treatment is unlikely to promote HCC recurrence. Rather, achieving SVR may prevent HCC recurrence and improve survival. In the DAA era, antiviral therapy should be actively considered for patients with a history of HCC, even after curative treatment, provided that continuous and strict surveillance is maintained.